After asthma: redefining airways diseases

The Lancet

Volumn 391, Issue 10118, 2018, Pages 350-400

  Pavord, Ian D ^a   Beasley, Richard ^b   Agusti, Alvar ^c,d   Anderson, Gary P ^e   Bel, Elisabeth ^f   Brusselle, Guy ^g,h   Cullinan, Paul ^j   Custovic, Adnan ⁱ   Ducharme, Francine M ^k   Fahy, John V ^l   Frey, Urs ^m   Gibson, Peter ^n,o   Heaney, Liam G ^p   Holt, Patrick G ^q   Humbert, Marc ^r,s,t   Lloyd, Clare M ^j   Marks, Guy ^u   Martinez, Fernando D ^v   Sly, Peter D ^w,x   von Mutius, Erika ^y   Wenzel, Sally ^z   Zar, Heather J ^aa   Bush, Andy ⁱ   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

ⁿ JOHN HUNTER HOSPITAL   (Australia)

^o UNIVERSITY OF NEWCASTLE   (Australia)

^p QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^q UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^r UNIVERSITÉ PARIS SACLAY   (France)

^s BICÊTRE HOSPITAL   (France)

^t CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^u UNIVERSITY OF NEW SOUTH WALES   (Australia)

^v UNIVERSITY OF ARIZONA   (United States)

^w LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^x Queensland University of Technology   (Australia)

^y LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^z UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^aa UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ASTHMA; COMORBIDITY; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; HEALTH CARE COST; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MORBIDITY; MORTALITY RATE; NONHUMAN; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PATIENT MONITORING; PERSONALIZED MEDICINE; POPULATION RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; TREND STUDY; WHEEZING; BREATHING DISORDER; PATHOPHYSIOLOGY; PUBLIC HEALTH; UNITED KINGDOM;

ASTHMA; HUMANS; PUBLIC HEALTH; RESPIRATION DISORDERS; UNITED KINGDOM;

EID: 85029208732     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30879-6     Document Type: Review

References (340)

1. Kola, I, Bell, J, A call to reform the taxonomy of human disease. Nat Rev Drug Discov 10 (2011), 641–642.
2. Brown, HM, Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 2 (1958), 1245–1247.
3. Hilvering, B, Xue, L, Pavord, ID, Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis 9 (2015), 135–145.
4. Barnes, PJ, New drugs for asthma. Nat Rev Drug Discov 3 (2004), 831–844.
5. Pavord, ID, Pizzichini, MM, Pizzichini, E, Hargreave, FE, The use of induced sputum to investigate airway inflammation. Thorax 52 (1997), 498–501.
6. Pavord, ID, Shaw, DE, Gibson, PG, Taylor, DR, Inflammometry to assess airway diseases. Lancet 372 (2008), 1017–1019.
7. Fajt, ML, Wenzel, SE, Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 135 (2015), 299–310.
8. Fahy, JV, Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol 15 (2015), 57–65.
9. Beasley, R, Weatherall, M, Shirtcliffe, P, Hancox, R, Reddel, HK, Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma?. J Allergy Clin Immunol 133 (2014), 39–41.
10. Green, RH, Brightling, CE, McKenna, S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
11. Jayaram, L, Pizzichini, MM, Cook, RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27 (2006), 483–494.
12. Pavord, ID, Korn, S, Howarth, P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
13. Fahy, JV, Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 117 (2006), 1230–1232.
14. Woolcock, A, Rubinfeld, AR, Seale, JP, et al. Thoracic society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust 151 (1989), 650–653.
15. Hargreave, FE, Dolovich, J, Newhouse, MT, The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 85 (1990), 1098–1111.
16. Guidelines for management of asthma in adults: I—Chronic persistent asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign. BMJ 301 (1990), 651–653.
17. Warner, JO, Götz, M, Landau, LI, et al. Management of asthma: a consensus statement. Arch Dis Child 64 (1989), 1065–1079.
18. Pappworth, ME, A primer of medicine, 5th edn., 1984, Butterworth-Heinemann, Oxford.
19. Ebmeier, S, Thayabaran, D, Braithwaite, I, Bénamara, C, Weatherall, M, Beasley, R, Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet, 2017 published online Aug 7. DOI:10.1016/S0140-6736(17)31448-4.
20. Martinez, FD, Vercelli, D, Asthma. Lancet 382 (2013), 1360–1372.
21. Barnes, PJ, Bonini, S, Seeger, W, Belvisi, MG, Ward, B, Holmes, A, Barriers to new drug development in respiratory disease. Eur Respir J 45 (2015), 1197–1207.
22. Rosenthal, M, CON: encouraging resistance to rule-based medicine is essential to improving outcomes. Thorax 70 (2015), 112–114.
23. Ciba Guest Symposium. Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions. Thorax, 14, 1959, 13.
24. A plea to abandon asthma as a disease concept. Lancet, 368, 2006, 705.
25. Haldar, P, Pavord, ID, Shaw, DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178 (2008), 218–224.
26. Siva, R, Green, RH, Brightling, CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29 (2007), 906–913.
27. Powell, H, Murphy, VE, Taylor, DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 378 (2011), 983–990.
28. Haldar, P, Brightling, CE, Hargadon, B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
29. Wenzel, S, Ford, L, Pearlman, D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
30. Hanania, NA, Noonan, M, Corren, J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70 (2015), 748–756.
31. Corren, J, Lemanske, RF, Hanania, NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
32. Wenzel, SE, Asthma: defining of the persistent adult phenotypes. Lancet 368 (2006), 804–813.
33. Salter, HH, Asthma, its pathology and treatment, 1860, John Churchill, London.
34. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 02-3659, 2002, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda.
35. Global Initiative for Asthma. 2017 GINA report, global strategy for asthma management and prevention. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/ (accessed June 5, 2017).
36. Cohen, SG, Sir John Floyer (1649–1734) British physician and pioneer clinical investigator. Allergy Proc 16 (1995), 328–329.
37. Sakula, A, Henry Hyde Salter (1823–71): a biographical sketch. Thorax 40 (1985), 887–888.
38. Rackemann, FM, A clinical survey of 1074 patients with asthma followed for two years. J Lab Clin Med 12 (1927), 1185–1197.
39. Hutchinson, J, Thorax. Todd, RB, (eds.) The cylopaedia of anatomy and physiology, 1852, Longmans, London, 1016–1087.
40. Tiffeneau, R, Drutel, P, Etude des facteurs alvéolaires et bronchiques de la ventilation pulmonaire. J Fr Med Chir Thorac 3 (1949), 401–431.
41. Fingleton, J, Weatherall, M, Beasley, R, Bronchodilator responsiveness: interpret with caution. Thorax 67 (2012), 667–668.
42. Controlled trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet 271 (1956), 803–806.
43. Brown, HM, How the first effective inhaled corticosteroid was almost discarded as useless. Ann Allergy Asthma Immunol 98 (2007), 602–603.
44. Brown, HM, Storey, G, George, WH, Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. BMJ 1 (1972), 585–590.
45. Selander, PER, Asthmatic Symptoms in the First Year of Life. Acta Paediatr 49 (1960), 265–269.
46. Fry, J, “Acute Wheezy Chests”. BMJ 1 (1961), 227–232.
47. Sporik, R, Holgate, ST, Cogswell, JJ, Natural history of asthma in childhood–a birth cohort study. Arch Dis Child 66 (1991), 1050–1053.
48. Cogswell, JJ, The wheezy child. Practitioner 217 (1976), 371–376.
49. Tai, A, Tran, H, Roberts, M, Clarke, N, Wilson, J, Robertson, CF, The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 69 (2014), 805–810.
50. Silverman, M, Out of the mouths of babes and sucklings: lessons from early childhood asthma. Thorax 48 (1993), 1200–1204.
51. Martinez, FD, Wright, AL, Taussig, LM, Holberg, CJ, Halonen, M, Morgan, WJ, the The Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med 332 (1995), 133–138.
52. Savenije, OE, Granell, R, Caudri, D, et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. J Allergy Clin Immunol 127 (2011), 1505–1512 e14.
53. Kerkhof, M, Boezen, HM, Granell, R, et al. Transient early wheeze and lung function in early childhood associated with chronic obstructive pulmonary disease genes. J Allergy Clin Immunol 133 (2014), 68–76 e1–4.
54. Langley, SJ, Goldthorpe, S, Custovic, A, Woodcock, A, Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Ann Allergy Asthma Immunol 91 (2003), 398–404.
55. Semic-Jusufagic, A, Belgrave, D, Pickles, A, et al. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-based birth cohort study. Lancet Respir Med 2 (2014), 621–630.
56. Sears, MR, Greene, JM, Willan, AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 349 (2003), 1414–1422.
57. Belgrave, DC, Buchan, I, Bishop, C, Lowe, L, Simpson, A, Custovic, A, Trajectories of lung function during childhood. Am J Respir Crit Care Med 189 (2014), 1101–1109.
58. Tromp, II, Kiefte-de Jong, JC, Lebon, A, et al. The introduction of allergenic foods and the development of reported wheezing and eczema in childhood: the Generation R study. Arch Pediatr Adolesc Med 165 (2011), 933–938.
59. Smith, JA, Drake, R, Simpson, A, Woodcock, A, Pickles, A, Custovic, A, Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med 177 (2008), 1358–1363.
60. Crestani, E, Guerra, S, Wright, AL, Halonen, M, Martinez, FD, Parental asthma as a risk factor for the development of early skin test sensitization in children. J Allergy Clin Immunol 113 (2004), 284–290.
61. Weitzman, M, Gortmaker, S, Walker, DK, Sobol, A, Maternal smoking and childhood asthma. Pediatrics 85 (1990), 505–511.
62. Tollånes, MC, Moster, D, Daltveit, AK, Irgens, LM, Cesarean section and risk of severe childhood asthma: a population-based cohort study. J Pediatr 153 (2008), 112–116.
63. Seidman, DS, Laor, A, Gale, R, Stevenson, DK, Danon, YL, Is low birth weight a risk factor for asthma during adolescence?. Arch Dis Child 66 (1991), 584–587.
64. Martinez, FD, Morgan, WJ, Wright, AL, Holberg, CJ, Taussig, LM, Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 319 (1988), 1112–1117.
65. Turner, SW, Palmer, LJ, Rye, PJ, et al. The relationship between infant airway function, childhood airway responsiveness, and asthma. Am J Respir Crit Care Med 169 (2004), 921–927.
66. Clarke, JR, Salmon, B, Silverman, M, Bronchial responsiveness in the neonatal period as a risk factor for wheezing in infancy. Am J Respir Crit Care Med 151 (1995), 1434–1440.
67. Palmer, LJ, Rye, PJ, Gibson, NA, Burton, PR, Landau, LI, Lesouëf, PN, Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am J Respir Crit Care Med 163 (2001), 37–42.
68. Bisgaard, H, Jensen, SM, Bønnelykke, K, Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med 185 (2012), 1183–1189.
69. Ege, MJ, Mayer, M, Normand, A-C, et al., the GABRIELA Transregio 22 Study Group. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 364 (2011), 701–709.
70. Langley, SJ, Goldthorpe, S, Craven, M, Morris, J, Woodcock, A, Custovic, A, Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 112 (2003), 362–368.
71. Simpson, A, John, SL, Jury, F, et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med 174 (2006), 386–392.
72. Custovic, A, Lazic, N, Simpson, A, Pediatric asthma and development of atopy. Curr Opin Allergy Clin Immunol 13 (2013), 173–180.
73. Simpson, A, Tan, VY, Winn, J, et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care Med 181 (2010), 1200–1206.
74. Guilbert, TW, Morgan, WJ, Zeiger, RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354 (2006), 1985–1997.
75. Bisgaard, H, Hermansen, MN, Loland, L, Halkjaer, LB, Buchvald, F, Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354 (2006), 1998–2005.
76. Murray, CS, Woodcock, A, Langley, SJ, Morris, J, Custovic, A, for the IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 368 (2006), 754–762.
77. Saglani, S, Payne, DN, Zhu, J, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med 176 (2007), 858–864.
78. Green, RH, Brightling, CE, McKenna, S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 27 (2006), 1144–1151.
79. Grainger, J, Woodman, K, Pearce, N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–7: a further case-control study. Thorax 46 (1991), 105–111.
80. Crane, J, Pearce, N, Flatt, A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1 (1989), 917–922.
81. Stolley, PD, Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105 (1972), 883–890.
82. Suissa, S, Ernst, P, Boivin, JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149 (1994), 604–610.
83. Beasley, R, Roche, WR, Roberts, JA, Holgate, ST, Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 139 (1989), 806–817.
84. Levy, ML, Winter, R, Asthma deaths: what now?. Thorax 70 (2015), 209–210.
85. Bossley, CJ, Saglani, S, Kavanagh, C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J 34 (2009), 1052–1059.
86. Greening, AP, Ind, PW, Northfield, M, Shaw, G, Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344 (1994), 219–224.
87. Pauwels, RA, Löfdahl, CG, Postma, DS, et al., the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997), 1405–1411.
88. Beasley, R, Perrin, K, Weatherall, M, Wijesinghe, M, Call for withdrawal of LABA single-therapy inhaler in asthma. Lancet 376 (2010), 750–751.
89. Beasley, R, Keil, U, von Mutius, E, et al., the The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 351 (1998), 1225–1232.
90. Global Asthma Network. The global asthma report. http://www.globalasthmareport.org, 2014 (accessed Feb 26, 2017).
91. To, T, Stanojevic, S, Moores, G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12, 2012, 204.
92. Kauppi, P, Linna, M, Martikainen, J, Mäkelä MJ, Haahtela, T, Follow-up of the Finnish Asthma Programme 2000-2010: reduction of hospital burden needs risk group rethinking. Thorax 68 (2013), 292–293.
93. Djukanović R, Harrison, T, Johnston, SL, et al., the INTERCIA Study Group. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 190 (2014), 145–154.
94. Hunter, CJ, Brightling, CE, Woltmann, G, Wardlaw, AJ, Pavord, ID, A comparison of the validity of different diagnostic tests in adults with asthma. Chest 121 (2002), 1051–1057.
95. Joyce, DP, Chapman, KR, Kesten, S, Prior diagnosis and treatment of patients with normal results of methacholine challenge and unexplained respiratory symptoms. Chest 109 (1996), 697–701.
96. Shaw, D, Green, R, Berry, M, et al. A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 21 (2012), 283–287.
97. Vestbo, J, Hurd, SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187 (2013), 347–365.
98. Marsh, SE, Travers, J, Weatherall, M, et al. Proportional classifications of COPD phenotypes. Thorax 63 (2008), 761–767.
99. Bateman, ED, Reddel, HK, van Zyl-Smit, RN, Agusti, A, The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. Lancet Respir Med 3 (2015), 719–728.
100. Pavord, I, Bush, A, Two Lovely Black Eyes; Oh, what a surprise!. Thorax 70 (2015), 609–610.
101. Gibson, PG, McDonald, VM, Asthma-COPD overlap 2015: now we are six. Thorax 70 (2015), 683–691.
102. Wain, LV, Shrine, N, Miller, S, et al. the UK Brain Expression Consortium (UKBEC), the OxGSK Consortium. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med 3 (2015), 769–781.
103. Pavord, ID, Haldar, P, Bradding, P, Wardlaw, AJ, Mepolizumab in refractory eosinophilic asthma. Thorax, 65, 2010, 370.
104. Green, RH, Brightling, CE, Woltmann, G, Parker, D, Wardlaw, AJ, Pavord, ID, Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57 (2002), 875–879.
105. Malinovschi, A, Fonseca, JA, Jacinto, T, Alving, K, Janson, C, Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 132 (2013), 821–827 e1–5.
106. Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
107. Smith, AD, Cowan, JO, Brassett, KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 172 (2005), 453–459.
108. Berry, MA, Shaw, DE, Green, RH, Brightling, CE, Wardlaw, AJ, Pavord, ID, The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 35 (2005), 1175–1179.
109. Hanania, NA, Wenzel, S, Rosén, K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (2013), 804–811.
110. Staton, TL, Choy, DF, Arron, JR, Biomarkers in the clinical development of asthma therapies. Biomarkers Med 10 (2016), 165–176.
111. Sabroe, I, Postma, D, Heijink, I, Dockrell, DH, The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 68 (2013), 1085–1087.
112. Leckie, MJ, ten Brinke, A, Khan, J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000), 2144–2148.
113. Leckie, MJ, Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2 (2003), 245–259.
114. Flood-Page, P, Swenson, C, Faiferman, I, et al., the International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007), 1062–1071.
115. O'Byrne, PM, The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 176 (2007), 1059–1060.
116. Nair, P, Pizzichini, MM, Kjarsgaard, M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
117. Liu, Y, Zhang, S, Li, DW, Jiang, SJ, Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One, 8, 2013, e59872.
118. Bel, EH, Wenzel, SE, Thompson, PJ, et al., the SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
119. Ortega, HG, Liu, MC, Pavord, ID, et al., the MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
120. Castro, M, Wenzel, SE, Bleecker, ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2 (2014), 879–890.
121. Castro, M, Zangrilli, J, Wechsler, ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
122. Wenzel, S, Castro, M, Corren, J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388 (2016), 31–44.
123. Anderson, GP, Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372 (2008), 1107–1119.
124. Peters, MC, McGrath, KW, Hawkins, GA, et al., the National Heart, Lung and Blood Institute Severe Asthma Research Program. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 4 (2016), 574–584.
125. Pavord, ID, Complex airway disease: an approach to assessment and management. Lancet Respir Med 1 (2013), 84–90.
126. Pavord, ID, Wardlaw, AJ, The A to E of airway disease. Clin Exp Allergy 40 (2010), 62–67.
127. Agusti, A, Bel, E, Thomas, M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47 (2016), 410–419.
128. Belgrave, D, Simpson, A, Custovic, A, Challenges in interpreting wheeze phenotypes: the clinical implications of statistical learning techniques. Am J Respir Crit Care Med 189 (2014), 121–123.
129. Hargreave, FE, Nair, P, The definition and diagnosis of asthma. Clin Exp Allergy 39 (2009), 1652–1658.
130. O'Reilly, R, Ullmann, N, Irving, S, et al. Increased airway smooth muscle in preschool wheezers who have asthma at school age. J Allergy Clin Immunol 131 (2013), 1024–1032 e1–16.
131. Wongtrakool, C, Wang, N, Hyde, DM, Roman, J, Spindel, ER, Prenatal nicotine exposure alters lung function and airway geometry through α7 nicotinic receptors. Am J Respir Cell Mol Biol 46 (2012), 695–702.
132. O'Byrne, PM, Inman, MD, Airway hyperresponsiveness. Chest 123:suppl (2003), 411S–416S.
133. Pavord, ID, Tattersfield, AE, Bronchoprotective role for endogenous prostaglandin E2. Lancet 345 (1995), 436–438.
134. Noble, PB, Pascoe, CD, Lan, B, et al. Airway smooth muscle in asthma: linking contraction and mechanotransduction to disease pathogenesis and remodelling. Pulm Pharmacol Ther 29 (2014), 96–107.
135. Stocks, J, Sonnappa, S, Early life influences on the development of chronic obstructive pulmonary disease. Ther Adv Respir Dis 7 (2013), 161–173.
136. Henderson, AJ, The child is father of the man: the importance of early life influences on lung development. Thorax 69 (2014), 976–977.
137. Cai, Y, Shaheen, SO, Hardy, R, Kuh, D, Hansell, AL, Birth weight, early childhood growth and lung function in middle to early old age: 1946 British birth cohort. Thorax 71 (2016), 916–922.
138. Lange, P, Celli, B, Agustí A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med 373 (2015), 111–122.
139. Håland, G, Carlsen, KC, Sandvik, L, et al., the ORAACLE. Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 355 (2006), 1682–1689.
140. Kusel, MM, Kebadze, T, Johnston, SL, Holt, PG, Sly, PD, Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur Respir J 39 (2012), 876–882.
141. Gray, DM, Turkovic, L, Willemse, L, et al. Lung Function in African Infants in the Drakenstein Child Health Study. Impact of Lower Respiratory Tract Illness. Am J Respir Crit Care Med 195 (2017), 212–220.
142. Sly, PD, Traffic-related air pollution: an avoidable exposure to improve respiratory health. Thorax 70 (2015), 3–4.
143. Abbott, LC, Winzer-Serhan, UH, Smoking during pregnancy: lessons learned from epidemiological studies and experimental studies using animal models. Crit Rev Toxicol 42 (2012), 279–303.
144. Stick, SM, Burton, PR, Gurrin, L, Sly, PD, LeSouëf, PN, Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet 348 (1996), 1060–1064.
145. Saglani, S, Malmström, K, Pelkonen, AS, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 171 (2005), 722–727.
146. Bolton, CE, Bush, A, Hurst, JR, Kotecha, S, McGarvey, L, Lung consequences in adults born prematurely. Thorax 70 (2015), 574–580.
147. Brusselle, GG, Maes, T, Bracke, KR, Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med 19 (2013), 977–979.
148. Haldar, P, Pavord, ID, Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 119 (2007), 1043–1052.
149. Douwes, J, Gibson, P, Pekkanen, J, Pearce, N, Non-eosinophilic asthma: importance and possible mechanisms. Thorax 57 (2002), 643–648.
150. Brusselle, GG, Vanderstichele, C, Jordens, P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68 (2013), 322–329.
151. Simpson, JL, Powell, H, Boyle, MJ, Scott, RJ, Gibson, PG, Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177 (2008), 148–155.
152. Nair, P, Gaga, M, Zervas, E, et al., the Study Investigators. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42 (2012), 1097–1103.
153. O'Byrne, PM, Metev, H, Puu, M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 4 (2016), 797–806.
154. Rennard, SI, Dale, DC, Donohue, JF, et al. CXCR2 Antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191 (2015), 1001–1011.
155. Han, MK, Tayob, N, Murray, S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 189 (2014), 1503–1508.
156. Andersson, CK, Adams, A, Nagakumar, P, et al. Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function. J Allergy Clin Immunol 139 (2016), 1819–1829.
157. Konstan, MW, Döring, G, Heltshe, SL, et al., the Investigators and Coordinators of BI Trial 543.45. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 13 (2014), 148–155.
158. Busse, WW, Holgate, S, Kerwin, E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 188 (2013), 1294–1302.
159. Wenzel, SE, Barnes, PJ, Bleecker, ER, et al., the T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179 (2009), 549–558.
160. Berry, MA, Hargadon, B, Shelley, M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 (2006), 697–708.
161. Busse, WW, Lemanske, RF Jr, Gern, JE, Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 376 (2010), 826–834.
162. Jackson, DJ, Johnston, SL, The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 125 (2010), 1178–1187 quiz 1188–89.
163. Kraft, M, The role of bacterial infections in asthma. Clin Chest Med 21 (2000), 301–313.
164. Pavord, ID, Chung, KF, Management of chronic cough. Lancet 371 (2008), 1375–1384.
165. Brightling, CE, Ward, R, Goh, KL, Wardlaw, AJ, Pavord, ID, Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 160 (1999), 406–410.
166. Abdulqawi, R, Dockry, R, Holt, K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385 (2015), 1198–1205.
167. Aurora, P, Stocks, J, Oliver, C, et al., the London Cystic Fibrosis Collaboration. Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med 169 (2004), 1152–1159.
168. Gappa, M, Pillow, JJ, Allen, J, Mayer, O, Stocks, J, Lung function tests in neonates and infants with chronic lung disease: lung and chest-wall mechanics. Pediatr Pulmonol 41 (2006), 291–317.
169. Lowe, L, Murray, CS, Custovic, A, Simpson, BM, Kissen, PM, Woodcock, A, the NAC Manchester Asthma and Allergy Study Group. Specific airway resistance in 3-year-old children: a prospective cohort study. Lancet 359 (2002), 1904–1908.
170. Asher, R, Straight and crooked thinking in medicine. BMJ 2 (1954), 460–462.
171. Doorn, PV, Folgering, HTM, Colla, P, Control of the end-tidal PCO2 in the hyperventilation syndrome: effects of biofeedback and breathing instructions compared. Bull Eur Physiopathol Respir 18 (1982), 829–836.
172. McDonald, VM, Higgins, I, Wood, LG, Gibson, PG, Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?. Thorax 68 (2013), 691–694.
173. Honkoop, PJ, Loijmans, RJ, Termeer, EH, et al., the Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. J Allergy Clin Immunol 135 (2015), 682–688 e11.
174. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/, 2016 (accessed Aug 3, 2017).
175. Bateman, ED, Boushey, HA, Bousquet, J, et al., the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004), 836–844.
176. Fleming, L, Bush, A, Fraction of exhaled nitric oxide measurements and asthma control: Are the numbers starting to add up?. J Allergy Clin Immunol 135 (2015), 689–690 e1.
177. Travers, J, Marsh, S, Williams, M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?. Thorax 62 (2007), 219–223.
178. Dweik, RA, Boggs, PB, Erzurum, SC, et al., the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184 (2011), 602–615.
179. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/, 2014 (accessed June 5, 2017).
180. Beran, D, Zar, HJ, Perrin, C, Menezes, AM, Burney, P, the Forum of International Respiratory Societies working group collaboration. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med 3 (2015), 159–170.
181. Pavord, ID, Agusti, A, Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur Respir J 47 (2016), 1299–1303.
182. Pereira, MU, Sly, PD, Pitrez, PM, et al. Nonatopic asthma is associated with helminth infections and bronchiolitis in poor children. Eur Respir J 29 (2007), 1154–1160.
183. da Silva, ER, Sly, PD, de Pereira, MU, et al. Intestinal helminth infestation is associated with increased bronchial responsiveness in children. Pediatr Pulmonol 43 (2008), 662–665.
184. Fleming, L, Tsartsali, L, Wilson, N, Regamey, N, Bush, A, Sputum inflammatory phenotypes are not stable in children with asthma. Thorax 67 (2012), 675–681.
185. Woodruff, PG, Modrek, B, Choy, DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180 (2009), 388–395.
186. Chowdhury, BA, Dal Pan, G, The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 362 (2010), 1169–1171.
187. Reddel, HK, Busse, WW, Pedersen, S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 389 (2017), 157–166.
188. Rabe, KF, Adachi, M, Lai, CKW, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004), 40–47.
189. Williams, LK, Pladevall, M, Xi, H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 114 (2004), 1288–1293.
190. Lemanske, RF Jr, Sorkness, CA, Mauger, EA, et al., the Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285 (2001), 2594–2603.
191. Chapman, KR, Barnes, NC, Greening, AP, Jones, PW, Pedersen, S, Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 65 (2010), 747–752.
192. Papi, A, Canonica, GW, Maestrelli, P, et al., the BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356 (2007), 2040–2052.
193. Martinez, FD, Chinchilli, VM, Morgan, WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 377 (2011), 650–657.
194. O'Byrne, PM, Bisgaard, H, Godard, PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005), 129–136.
195. Rabe, KF, Atienza, T, Magyar, P, Larsson, P, Jorup, C, Lalloo, UG, Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006), 744–753.
196. Calhoun, WJ, Ameredes, BT, King, TS, et al., the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 308 (2012), 987–997.
197. Sovani, MP, Whale, CI, Oborne, J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract 58 (2008), 37–43.
198. Holt, S, Suder, A, Weatherall, M, Cheng, S, Shirtcliffe, P, Beasley, R, Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 323 (2001), 253–256.
199. Powell, H, Gibson, P, High dose versus low dose inhaled corticosteroids as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev, 2004 CD004109.
200. Lemanske, RF Jr, Mauger, DT, Sorkness, CA, et al., the Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 362 (2010), 975–985.
201. Oborne, J, Mortimer, K, Hubbard, RB, Tattersfield, AE, Harrison, TW, Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 180 (2009), 598–602.
202. Harrison, TW, Tattersfield, AE, Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58 (2003), 258–260.
203. Rikkers-Mutsaerts, ER, Winters, AE, Bakker, MJ, et al., the SMASHING Study Group. Internet-based self-management compared with usual care in adolescents with asthma: a randomized controlled trial. Pediatr Pulmonol 47 (2012), 1170–1179.
204. van Nimwegen, FA, Penders, J, Stobberingh, EE, et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol 128 (2011), 948–955.
205. von Mutius, E, Childhood experiences take away your breath as a young adult. Am J Respir Crit Care Med 165 (2002), 1467–1468.
206. Loss, GJ, Depner, M, Hose, AJ, et al., the PASTURE (Protection against Allergy Study in Rural Environments) Study Group. The Early Development of Wheeze. Environmental Determinants and Genetic Susceptibility at 17q21. Am J Respir Crit Care Med 193 (2016), 889–897.
207. Pekkanen, J, Hyvärinen, A, Haverinen-Shaughnessy, U, Korppi, M, Putus, T, Nevalainen, A, Moisture damage and childhood asthma: a population-based incident case-control study. Eur Respir J 29 (2007), 509–515.
208. Jensen, ME, Wood, LG, Gibson, PG, Obesity and childhood asthma—mechanisms and manifestations. Curr Opin Allergy Clin Immunol 12 (2012), 186–192.
209. Salam, MT, Li, YF, Langholz, B, Gilliland, FD, the Children's Health Study. Early-life environmental risk factors for asthma: findings from the Children's Health Study. Environ Health Perspect 112 (2004), 760–765.
210. Al-Sahab, B, Hamadeh, MJ, Ardern, CI, Tamim, H, Early menarche predicts incidence of asthma in early adulthood. Am J Epidemiol 173 (2011), 64–70.
211. McGeachie, MJ, Yates, KP, Zhou, X, et al., the CAMP Research Group. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med 374 (2016), 1842–1852.
212. Calverley, PM, Anderson, JA, Celli, B, et al., the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
213. Abramson, MJ, Kaushik, S, Benke, GP, et al. Symptoms and lung function decline in a middle-aged cohort of males and females in Australia. Int J Chron Obstruct Pulmon Dis 11 (2016), 1097–1103.
214. Vestbo, J, Agusti, A, Wouters, EF, et al., the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 189 (2014), 1022–1030.
215. O'Byrne, PM, Pedersen, S, Lamm, CJ, Tan, WC, Busse, WW, the START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179 (2009), 19–24.
216. Bønnelykke, K, Vissing, NH, Sevelsted, A, Johnston, SL, Bisgaard, H, Association between respiratory infections in early life and later asthma is independent of virus type. J Allergy Clin Immunol 136 (2015), 81–86 e4.
217. Jaberolansar, N, Toth, I, Young, PR, Skwarczynski, M, Recent advances in the development of subunit-based RSV vaccines. Expert Rev Vaccines 15 (2016), 53–68.
218. Mochizuki, H, Kusuda, S, Okada, K, Yoshihara, S, Furuya, H, Simões, EA, Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing: 6 year follow up study. Am J Respir Crit Care Med, 2017 published online Feb 2. DOI:10.1164/rccm.201609-1812OC.
219. Nagakumar, P, Denney, L, Fleming, L, Bush, A, Lloyd, CM, Saglani, S, Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J Allergy Clin Immunol 137 (2016), 624–626.
220. Stern, DA, Morgan, WJ, Halonen, M, Wright, AL, Martinez, FD, Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 372 (2008), 1058–1064.
221. Johnston, IDA, Strachan, DP, Anderson, HR, Effect of pneumonia and whooping cough in childhood on adult lung function. N Engl J Med 338 (1998), 581–587.
222. Kröner, C, Reu, S, Teusch, V, et al. Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. Eur Respir J 46 (2015), 197–206.
223. Nogee, LM, Dunbar, AE 3rd, Wert, SE, Askin, F, Hamvas, A, Whitsett, JA, A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344 (2001), 573–579.
224. Schulman, SR, Canada, AT, Fryer, AD, Winsett, DW, Costa, DL, Airway hyperreactivity produced by short-term exposure to hyperoxia in neonatal guinea pigs. Am J Physiol 272 (1997), L1211–L1216.
225. Li, X, Howard, TD, Moore, WC, et al. Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol 127 (2011), 1457–1465.
226. Mason, PH, Degeneracy: Demystifying and destigmatizing a core concept in systems biology. Complexity 20 (2015), 12–21.
227. Tieri, P, Grignolio, A, Zaikin, A, et al. Network, degeneracy and bow tie. Integrating paradigms and architectures to grasp the complexity of the immune system. Theor Biol Med Model, 7, 2010, 32.
228. Mellen, NM, Degeneracy as a substrate for respiratory regulation. Respir Physiol Neurobiol 172 (2010), 1–7.
229. Mayer-Kress, G, Liu, Y-T, Newell, KM, Complex systems and human movement. Complexity 12 (2006), 40–51.
230. Atamas, N, Atamas, MS, Atamas, F, Atamas, SP, Non-local competition drives both rapid divergence and prolonged stasis in a model of speciation in populations with degenerate resource consumption. Theor Biol Med Model, 9, 2012, 56.
231. Lazic, N, Roberts, G, Custovic, A, et al. Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts. Allergy 68 (2013), 764–770.
232. Belgrave, DC, Granell, R, Simpson, A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med, 11, 2014, e1001748.
233. Bunyavanich, S, Schadt, EE, Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol 135 (2015), 31–42.
234. Chen, W, Boutaoui, N, Brehm, JM, et al. ADCYAP1R1 and asthma in Puerto Rican children. Am J Respir Crit Care Med 187 (2013), 584–588.
235. Yang, IV, Pedersen, BS, Liu, A, et al. DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol 136 (2015), 69–80.
236. Gunawardhana, LP, Baines, KJ, Mattes, J, Murphy, VE, Simpson, JL, Gibson, PG, Differential DNA methylation profiles of infants exposed to maternal asthma during pregnancy. Pediatr Pulmonol 49 (2014), 852–862.
237. Raedler, D, Schaub, B, Immune mechanisms and development of childhood asthma. Lancet Respir Med 2 (2014), 647–656.
238. Stein, MM, Hrusch, CL, Gozdz, J, et al. Innate immunity and asthma risk in Amish and Hutterite farm children. N Engl J Med 375 (2016), 411–421.
239. Bäckhed, F, Roswall, J, Peng, Y, et al. Dynamics and Stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17 (2015), 690–703.
240. Latzin, P, Röösli, M, Huss, A, Kuehni, CE, Frey, U, Air pollution during pregnancy and lung function in newborns: a birth cohort study. Eur Respir J 33 (2009), 594–603.
241. Kuehni, CE, Strippoli, MP, Low, N, Brooke, AM, Silverman, M, Wheeze and asthma prevalence and related health-service use in white and south Asian pre-schoolchildren in the United Kingdom. Clin Exp Allergy 37 (2007), 1738–1746.
242. von Mutius, E, The microbial environment and its influence on asthma prevention in early life. J Allergy Clin Immunol 137 (2016), 680–689.
243. Meyers, DA, Bleecker, ER, Holloway, JW, Holgate, ST, Asthma genetics and personalised medicine. Lancet Respir Med 2 (2014), 405–415.
244. Wild, CP, The exposome: from concept to utility. Int J Epidemiol 41 (2012), 24–32.
245. Guerra, S, Halonen, M, Vasquez, MM, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med 3 (2015), 613–620.
246. Custovic, A, Ainsworth, J, Arshad, H, et al. The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together. Thorax 70 (2015), 799–801.
247. Horikoshi, M, Beaumont, RN, Day, FR, et al. the CHARGE Consortium Hematology Working Group, the Early Growth Genetics (EGG) Consortium. Genome-wide associations for birth weight and correlations with adult disease. Nature 538 (2016), 248–252.
248. Holt, PG, Sly, PD, Martinez, FD, et al. Drug development strategies for asthma: in search of a new paradigm. Nat Immunol 5 (2004), 695–698.
249. Holt, PG, Sly, PD, Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med 18 (2012), 726–735.
250. Durham, SR, Walker, SM, Varga, E-M, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999), 468–475.
251. Kulus, M, Hébert, J, Garcia, E, Fowler Taylor, A, Fernandez Vidaurre, C, Blogg, M, Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 26 (2010), 1285–1293.
252. Busse, WW, Morgan, WJ, Gergen, PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364 (2011), 1005–1015.
253. Collet, JP, Shapiro, P, Ernst, P, Renzi, T, Ducruet, T, Robinson, A, Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. Am J Respir Crit Care Med 156 (1997), 1719–1724.
254. Razi, CH, Harmancı K, Abacı A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol 126 (2010), 763–769.
255. Devulapalli, CS, Carlsen, KC, Håland, G, et al. Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. Thorax 63 (2008), 8–13.
256. Castro-Rodríguez, JA, Holberg, CJ, Wright, AL, Martinez, FD, A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 162 (2000), 1403–1406.
257. Klaassen, EM, van de Kant, KD, Jöbsis, Q, et al. Exhaled biomarkers and gene expression at preschool age improve asthma prediction at 6 years of age. Am J Respir Crit Care Med 191 (2015), 201–207.
258. Holt, PG, Sly, PD, Sampson, HA, et al. Prophylactic use of sublingual allergen immunotherapy in high risk children: a pilot study. J Allergy Clin Immunol 132 (2013), 991–993.
259. Du Toit, G, Roberts, G, Sayre, PH, et al., the LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 372 (2015), 803–813.
260. Zolkipli, Z, Roberts, G, Cornelius, V, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol 136 (2015), 1541–1547 e1, 11.
261. Özdemir, O, Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 160 (2010), 295–304.
262. Bisgaard, H, Stokholm, J, Chawes, BL, et al. Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. N Engl J Med 375 (2016), 2530–2539.
263. Beeh, KM, Kanniess, F, Wagner, F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 131 (2013), 866–874.
264. Lenney, W, Perry, S, Price, D, Clinical trials and tribulations: the MASCOT study. Thorax 66 (2011), 457–458.
265. Giacoia, GP, Incentive to study drugs in children and other governmental initiatives: will patients with asthma benefit?. J Allergy Clin Immunol 106:suppl 3 (2000), S118–S124.
266. Reddel, HK, Taylor, DR, Bateman, ED, et al., the American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180 (2009), 59–99.
267. Reddel, H, Ware, S, Marks, G, Salome, C, Jenkins, C, Woolcock, A, Differences between asthma exacerbations and poor asthma control. Lancet 353 (1999), 364–369.
268. Donaldson, GC, Wedzicha, JA, COPD exacerbations. 1: Epidemiology. Thorax 61 (2006), 164–168.
269. Goss, CH, Burns, JL, Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62 (2007), 360–367.
270. Blakey, JD, Woolnough, K, Fellows, J, Walker, S, Thomas, M, Pavord, ID, Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm. Prim Care Respir J 22 (2013), 344–352.
271. Pizzichini, MM, Pizzichini, E, Efthimiadis, A, et al. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med 158 (1998), 1178–1184.
272. Turner, MO, Hussack, P, Sears, MR, Dolovich, J, Hargreave, FE, Exacerbations of asthma without sputum eosinophilia. Thorax 50 (1995), 1057–1061.
273. Eisner, MD, Katz, PP, Yelin, EH, Shiboski, SC, Blanc, PD, Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res 2 (2001), 53–60.
274. Panickar, J, Lakhanpaul, M, Lambert, PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 360 (2009), 329–338.
275. Ermers, MJJ, Rovers, MM, van Woensel, JB, Kimpen, JLL, Bont, LJ, The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ, 338, 2009, b897.
276. Castro-Rodriguez, JA, Rodrigo, GJ, Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 123 (2009), e519–e525.
277. Nwokoro, C, Pandya, H, Turner, S, et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial. Lancet Respir Med 2 (2014), 796–803.
278. Ducharme, FM, Tse, SM, Chauhan, B, Diagnosis, management, and prognosis of preschool wheeze. Lancet 383 (2014), 1593–1604.
279. Bafadhel, M, McKenna, S, Terry, S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184 (2011), 662–671.
280. Bafadhel, M, Davies, L, Calverley, PM, Aaron, SD, Brightling, CE, Pavord, ID, Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 44 (2014), 789–791.
281. Bafadhel, M, McKenna, S, Terry, S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186 (2012), 48–55.
282. Ghazi, A, Trikha, A, Calhoun, WJ, Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. Expert Opin Biol Ther 12 (2012), 113–118.
283. Nowak, RM, Parker, JM, Silverman, RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 33 (2014), 14–20.
284. Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2013), 343–373.
285. Heaney, LG, Robinson, DS, Severe asthma treatment: need for characterising patients. Lancet 365 (2005), 974–976.
286. Heaney, LG, Horne, R, Non-adherence in difficult asthma: time to take it seriously. Thorax 67 (2012), 268–270.
287. Pilcher, J, Holliday, M, Ebmeier, S, et al. Validation of a metered dose inhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res, 3, 2016, e000128.
288. McNicholl, DM, Stevenson, M, McGarvey, LP, Heaney, LG, The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 186 (2012), 1102–1108.
289. Mastronarde, JG, Anthonisen, NR, Castro, M, et al., the American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 360 (2009), 1487–1499.
290. Spivak, H, Smith, CD, Phichith, A, Galloway, K, Waring, JP, Hunter, JG, Asthma and gastroesophageal reflux: fundoplication decreases need for systemic corticosteroids. J Gastrointest Surg 3 (1999), 477–482.
291. Moore, WC, Meyers, DA, Wenzel, SE, et al., the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181 (2010), 315–323.
292. Beuther, DA, Weiss, ST, Sutherland, ER, Obesity and asthma. Am J Respir Crit Care Med 174 (2006), 112–119.
293. van Huisstede, A, Rudolphus, A, Castro Cabezas, M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 70 (2015), 659–667.
294. Pavord, ID, Brightling, CE, Woltmann, G, Wardlaw, AJ, Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353 (1999), 2213–2214.
295. Fleming, L, Wilson, N, Regamey, N, Bush, A, Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 67 (2012), 193–198.
296. Walsh, LJ, Wong, CA, Oborne, J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 56 (2001), 279–284.
297. Sweeney, J, Patterson, CC, Menzies-Gow, A, et al., the British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 71 (2016), 339–346.
298. Chung, KF, Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma. Expert Opin Pharmacother 5 (2004), 439–446.
299. Gonem, S, Berair, R, Singapuri, A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 4 (2016), 699–707.
300. Gauvreau, GM, O'Byrne, PM, Boulet, LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370 (2014), 2102–2110.
301. Castro, M, Rubin, AS, Laviolette, M, et al., the AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181 (2010), 116–124.
302. Cox, G, Thomson, NC, Rubin, AS, et al., the AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med 356 (2007), 1327–1337.
303. de Lange, EE, Altes, TA, Patrie, JT, et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 130 (2006), 1055–1062.
304. Woodcock, A, Bakerly, ND, New, JP, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med, 15, 2015, 160.
305. Price, D, Brusselle, G, Roche, N, Freeman, D, Chisholm, A, Real-world research and its importance in respiratory medicine. Breathe 11 (2015), 26–38.
306. Walker, SM, Akdis, C, Dahlen, SE, et al. Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument. Clin Exp Allergy 46 (2016), 1136–1138.
307. Patel, M, Pilcher, J, Pritchard, A, et al., the SMART Study Group. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 1 (2013), 32–42.
308. Belgrave, DC, Custovic, A, Simpson, A, Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management. Expert Rev Clin Immunol 9 (2013), 921–936.
309. Van Wonderen, KE, Van Der Mark, LB, Mohrs, J, Bindels, PJ, Van Aalderen, WM, Ter Riet, G, Different definitions in childhood asthma: how dependable is the dependent variable?. Eur Respir J 36 (2010), 48–56.
310. Barabási, AL, Gulbahce, N, Loscalzo, J, Network medicine: a network-based approach to human disease. Nat Rev Genet 12 (2011), 56–68.
311. Torgerson, DG, Ampleford, EJ, Chiu, GY, et al. the Mexico City Childhood Asthma Study (MCAAS) the Children's Health Study (CHS) and HARBORS study the Genetics of Asthma in Latino Americans (GALA) Study Study of Genes-Environment and Admixture in Latino Americans (GALA2) Study of African Americans, Asthma, Genes & Environments (SAGE) the Childhood Asthma Research and Education (CARE) Network the Childhood Asthma Management Program (CAMP) the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE), the Genetic Research on Asthma in African Diaspora (GRAAD) Study. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet 43 (2011), 887–892.
312. Ober, C, Yao, T-C, The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 242 (2011), 10–30.
313. Moffatt, MF, Gut, IG, Demenais, F, et al., the GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 363 (2010), 1211–1221.
314. Vercelli, D, Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 8 (2008), 169–182.
315. Bønnelykke, K, Sleiman, P, Nielsen, K, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet 46 (2014), 51–55.
316. Bochkov, YA, Watters, K, Ashraf, S, et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc Natl Acad Sci USA 112 (2015), 5485–5490.
317. Eder, W, Ege, MJ, von Mutius, E, The asthma epidemic. N Engl J Med 355 (2006), 2226–2235.
318. Simpson, A, Martinez, FD, The role of lipopolysaccharide in the development of atopy in humans. Clin Exp Allergy 40 (2010), 209–223.
319. Custovic, A, Rothers, J, Stern, D, et al. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies. J Allergy Clin Immunol 127 (2011), 390–397 e1–9.
320. Custovic, A, Simpson, A, Environmental allergen exposure, sensitisation and asthma: from whole populations to individuals at risk. Thorax 59 (2004), 825–827.
321. Scott, M, Roberts, G, Kurukulaaratchy, RJ, Matthews, S, Nove, A, Arshad, SH, Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. Thorax 67 (2012), 1046–1051.
322. Sears, MR, Taylor, DR, Print, CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 (1990), 1391–1396.
323. Kraan, J, Koëter, GH, vd Mark, TW, Sluiter, HJ, de Vries, K, Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 76 (1985), 628–636.
324. Berry, SM, Connor, JT, Lewis, RJ, The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313 (2015), 1619–1620.
325. Persson, CGA, Rebuttal from Dr. Persson. Am J Respir Crit Care Med, 166, 2002, 8.
326. Clarke, DL, Davis, NH, Majithiya, JB, et al. Development of a mouse model mimicking key aspects of a viral asthma exacerbation. Clin Sci (Lond) 126 (2014), 567–580.
327. Bartlett, NW, Walton, RP, Edwards, MR, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 14 (2008), 199–204.
328. Bisgaard, H, Hermansen, MN, Buchvald, F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 357 (2007), 1487–1495.
329. Ostman, S, Rask, C, Wold, AE, Hultkrantz, S, Telemo, E, Impaired regulatory T cell function in germ-free mice. Eur J Immunol 36 (2006), 2336–2346.
330. Gollwitzer, ES, Marsland, BJ, Microbiota abnormalities in inflammatory airway diseases—Potential for therapy. Pharmacol Ther 141 (2014), 32–39.
331. Esch, EW, Bahinski, A, Huh, D, Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 14 (2015), 248–260.
332. Summers, C, Singh, NR, White, JF, et al. Pulmonary retention of primed neutrophils: a novel protective host response, which is impaired in the acute respiratory distress syndrome. Thorax 69 (2014), 623–629.
333. Sandström, T, Bjermer, L, Rylander, R, Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur Respir J 5 (1992), 992–996.
334. Silverman, M, Wilson, N, Asthma–time for a change of name?. Arch Dis Child 77 (1997), 62–64 discussion 64–65.
335. Vilajeliu, A, García-Basteiro, AL, Bayas, JM, Protecting newborns against pertussis: the value of vaccinating during pregnancy. Expert Rev Vaccines 14 (2015), 1051–1053.
336. Jochmann, A, Artusio, L, Robson, K, et al. Infection and inflammation in induced sputum from preschool children with chronic airways diseases. Pediatr Pulmonol 51 (2016), 778–786.
337. Putcha, N, Barr, RG, Han, MK, et al., the SPIROMICS Investigators. Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016 thoraxjnl-2015-207487.
338. Agustí A, Antó JM, Auffray, C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med 191 (2015), 391–401.
339. Floyer, J, A treatise of the asthma, 1698, R. Wilkins, London.
340. Osler, W, The principles and practice of medicine, 1894, Appleton, New York.